ISD-Immunotech Overview
- Year Founded
-
2007
- Status
-
Out of Business
- Employees
-
5
- Latest Deal Type
-
Out of Business
ISD-Immunotech General Information
Description
Developer of sting modulators designed to treat severe systemic lupus erythematosus or lupus by targeting the sting pathway. The company offers therapy that works by dampening the action of an intracellular protein called stimulator of interferon genes, and when triggered, it ramps up the production of inflammatory proteins called interferons and cytokines, which boost the immune system, helping patients to fight against pathogen invaders like bacteria and viruses.
Contact Information
Website
www.isd-immunotech.comCorporate Office
- Stærmosevej 12
- East
- 7120 Vejle
- Denmark
Corporate Office
- Stærmosevej 12
- East
- 7120 Vejle
- Denmark
ISD-Immunotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Out of Business | 01-Mar-2023 | Completed | Out of Business | |||
| 6. Seed Round | 13-Oct-2021 | Completed | Generating Revenue | |||
| 5. Debt - General | Completed | Startup | ||||
| 4. Seed Round | 01-Jul-2020 | Completed | Startup | |||
| 3. Seed Round | 19-Apr-2018 | Completed | Startup | |||
| 2. Accelerator/Incubator | 01-Jan-2017 | $44.8K | $44.8K | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2007 | Completed | Startup |
ISD-Immunotech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 14,222 | $11.03 | $11.03 | 1x | $11.03 | 6.32% | ||
| Ordinary | 3,000 | $16.51 | $16.51 | 1x | $16.51 | 1.33% |
ISD-Immunotech Patents
ISD-Immunotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2983706-A2 | Use of immune suppressive domains as medicaments | Active | 10-Apr-2013 | ||
| EP-2983706-B1 | Use of immune suppressive domains as medicaments | Active | 10-Apr-2013 | ||
| EP-3906931-A2 | Use of immune suppressive domains as medicaments | Inactive | 10-Apr-2013 | ||
| EP-3906931-A3 | Use of immune suppressive domains as medicaments | Inactive | 10-Apr-2013 | ||
| US-11484567-B2 | Use of immune suppressive domains as medicaments | Active | 10-Apr-2013 | A61K39/0008 |
ISD-Immunotech Signals
ISD-Immunotech FAQs
-
When was ISD-Immunotech founded?
ISD-Immunotech was founded in 2007.
-
Where is ISD-Immunotech headquartered?
ISD-Immunotech is headquartered in Vejle, Denmark.
-
What is the size of ISD-Immunotech?
ISD-Immunotech has 5 total employees.
-
What industry is ISD-Immunotech in?
ISD-Immunotech’s primary industry is Drug Discovery.
-
Is ISD-Immunotech a private or public company?
ISD-Immunotech is a Private company.
-
What is ISD-Immunotech’s current revenue?
The current revenue for ISD-Immunotech is .
-
How much funding has ISD-Immunotech raised over time?
ISD-Immunotech has raised $2.3M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process